OncoMatch/Clinical Trials/NCT05726110

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Is NCT05726110 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for relapsed or refractory acute myeloid leukemia.

Phase 3RecruitingShanxi Bethune HospitalNCT05726110Data as of May 2026

Treatment: Selinexor · Homoharringtonine · Daunorubicin · Cytarabine · Granulocyte Colony-Stimulating Factor · Aclacinomycin — This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify